{"created":"2023-06-20T16:49:49.788718+00:00","id":22133,"links":{},"metadata":{"_buckets":{"deposit":"26809cd8-b4a1-4753-b529-e3cbf5fe84c4"},"_deposit":{"created_by":3,"id":"22133","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"22133"},"status":"published"},"_oai":{"id":"oai:kindai.repo.nii.ac.jp:00022133","sets":["14:2667:4710"]},"author_link":["3365"],"control_number":"22133","item_8_biblio_info_21":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2021","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"8","bibliographicPageStart":"1","bibliographic_titles":[{"bibliographic_title":"科学研究費助成事業研究成果報告書 (2020)"}]}]},"item_8_description_25":{"attribute_name":"リンクURL","attribute_value_mlt":[{"subitem_description":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-18K06710/","subitem_description_type":"Other"}]},"item_8_description_33":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"研究成果の概要（和文）：ButyrateおよびTNBS誘起関連痛覚過敏および結腸過敏にCav3.2 T型カルシムチャネルが重要な役割を持つことが明らかになった。一方、CB1およびCB2受容体刺激薬は本モデルにおいて明確な効果を示さなかった。そこで既存医薬品の中でT型カルシムチャネル阻害活性を有する抗不整脈薬や抗狭心症薬bepridilや定型抗精神病薬pimozideの有効性を検討したところ、強い結腸痛抑制効果が認められた。したがって、bepridilやpimozideをリード化合物としたよりT型カルシムチャネルに選択性の高い薬物の開発は、過敏性腸症候群の新たな治療戦略となりうることが明らかとなった。研究成果の概要（英文）：The present study demonstrates that Cav3.2 T-type Ca2+ channels play an important role in butyrate and TNBS-induced colonic pain. On the other hands, CB1 or CB2 receptor agonist did not show a clear effect in these models. We also clarified that, among existing drug, bepridil, an antiarrhythmic drug and antianginal drug, and pimozide, a typical antipsychotic drug, markedly reversed colonic pain. Therefore, our findings support that the development of a more selective drug for T-type Ca2+ channel using bepridil or pimozide as a lead compound could be a new therapeutic strategy for irritable bowel syndrome.","subitem_description_type":"Abstract"}]},"item_8_description_36":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"研究種目：基盤研究(C);  研究期間：2018～2020;   課題番号：18K06710;   研究分野：薬理学;   科研費の分科・細目：","subitem_description_type":"Other"}]},"item_8_description_37":{"attribute_name":"資源タイプ(WEKO2)","attribute_value_mlt":[{"subitem_description":"Research Paper","subitem_description_type":"Other"}]},"item_8_description_41":{"attribute_name":"フォーマット","attribute_value_mlt":[{"subitem_description":"application/pdf","subitem_description_type":"Other"}]},"item_8_publisher_14":{"attribute_name":"出版者 名前","attribute_value_mlt":[{"subitem_publisher":"近畿大学"}]},"item_8_text_10":{"attribute_name":"著者 役割","attribute_value_mlt":[{"subitem_text_value":"研究代表者"}]},"item_8_text_7":{"attribute_name":"著者(英)","attribute_value_mlt":[{"subitem_text_language":"en","subitem_text_value":"Tsubota, Maho"}]},"item_8_text_8":{"attribute_name":"著者 所属","attribute_value_mlt":[{"subitem_text_value":"近畿大学薬学部; 講師"}]},"item_8_text_9":{"attribute_name":"著者所属(翻訳)","attribute_value_mlt":[{"subitem_text_value":"Kindai University"}]},"item_8_version_type_12":{"attribute_name":"版","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_be7fb7dd8ff6fe43","subitem_version_type":"NA"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"坪田, 真帆"},{"creatorName":"ツボタ, マホ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{"nameIdentifier":"3365","nameIdentifierScheme":"WEKO"},{"nameIdentifier":"90510123","nameIdentifierScheme":"NRID","nameIdentifierURI":"https://nrid.nii.ac.jp/ja/search/?kw=90510123"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-11-08"}],"displaytype":"detail","filename":"18K06710seika.pdf","filesize":[{"value":"336.1 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"18K06710seika.pdf","url":"https://kindai.repo.nii.ac.jp/record/22133/files/18K06710seika.pdf"},"version_id":"1ff16b80-361a-496f-99cc-936dd669f52f"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"過敏性腸症候群","subitem_subject_scheme":"Other"},{"subitem_subject":"T型カルシウム","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"research report","resourceuri":"http://purl.org/coar/resource_type/c_18ws"}]},"item_title":"カンナビノイド受容体とT型Caチャネルを標的とする過敏性腸症候群の新規治療戦略","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"カンナビノイド受容体とT型Caチャネルを標的とする過敏性腸症候群の新規治療戦略","subitem_title_language":"ja"},{"subitem_title":"New therapeutic strategies for irritable bowel syndrome targeting cannabinoid receptors and T-type calcium channels","subitem_title_language":"en"}]},"item_type_id":"8","owner":"3","path":["4710"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2021-11-08"},"publish_date":"2021-11-08","publish_status":"0","recid":"22133","relation_version_is_last":true,"title":["カンナビノイド受容体とT型Caチャネルを標的とする過敏性腸症候群の新規治療戦略"],"weko_creator_id":"3","weko_shared_id":-1},"updated":"2023-08-13T06:07:26.176891+00:00"}